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Background: Quality of life has become a part of the evaluation criteria for cancer
therapy. The aim of this study was to evaluate the quality of life in breast cancer patients
under chemotherapy regimens that contained doxorubicin and cyclophosphamide
(AC) compared to paclitaxel and gemcitabine (PG).
Methods: This cohort study evaluated 100 women with breast cancer treated by
doxorubicin and cyclophosphamide or gemcitabine and paclitaxel regimens. We used the
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-
Core 30 to assess health related quality of life at the beginning and end of chemotherapy.
Data were analyzed by the independent t-test at a significance level of 0.05.
Results: Most of the 100 patients were married (68%), aged 41-50 years (36%),
non-college educated (76%), and had insurance (97%). The mean quality of life scores
at the first session of chemotherapy and prior to the onset of treatment-related adverse
events were 71.33 for the doxorubicin and cyclophosphamide groups and 71.15 for the
gemcitabine and paclitaxel groups. Analysis of the European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire-Core 30 at the last chemotherapy
session showed that the quality of life in both groups deteriorated as a result of side
effects. The mean of quality of life scores at the first session of chemotherapy were 66.49
for the doxorubicin and cyclophosphamide group and 59.99 for the gemcitabine and
paclitaxel group.
Conclusion: Strategies to improve the emotional and role functions of the patients
who undergo treatment should be given priority. Financial difficulties faced by breast
cancer patients should be addressed from a policy making level at the initiating health
financing system.
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Introduction
Cancer is the second most common cause of
death in developed countries after cardiovascular
disease and the third most common reason for
mortality in developing countries, with an
estimated 7.6 million deaths worldwide in 2008.1,2
Breast cancer is the most common type of tumor
and the leading cause of cancer deaths in women.
It accounts for 23% (1,380,000) of all new cancer
cases and 14% (458,400) of all cancer deaths.2 In
Iran, breast cancer is the most common cancer in
women, and accounts for 21.4% of all cancers
among females.3 An increased trend for breast
cancer mortality in Iran from 1.40 to 3.52 per
100,000 (1995 to 2004) has been reported.4 Breast
cancer affects Iranian women at least one decade
earlier than their counterparts in developed
countries.5 The majority of cases in developed
countries are detected and cured at stage I. In
Iran, many cases are detected in the second or third
stages.6 There are several therapeutic approaches
to treat these patients. Each has its own particular
effects and complications which can determine a
patient’s survival and quality of life (QOL).7 Due
to the lack of a comprehensive reference protocol
for the use of neoadjuvant therapy, various
therapeutic regimens have been implemented in
the treatment of breast cancer.8 Traditionally,
neoadjuvant chemotherapy, also known as primary
or preoperative chemotherapy, has been used to
treat women with locally advanced breast cancer
in an attempt to render the tumor operable.9,10
Anthracycline and taxane-based regimens are the
backbones of most neoadjuvant chemotherapy
protocols for breast cancer.11 The AC regimen of
doxorubicin 60 mg/m2 and cyclophosphamide
600 mg/m2 every 3 weeks for 4 cycles has been
a standard chemotherapy option since 1975.12
The incorporation of anthracyclines further
improves response rates and time to progression
beyond those obtained with combinations that
consist of medications other than
anthracyclines.13,14 Alternatively, the PG regimen
that consists of paclitaxel 175 mg/m2 and
gemcitabine 1000 mg/m2 every 3 weeks for 4
cycles, as a neoadjuvant regimen, is used in an
attempt to obtain a better response.15 Diagnosis of
breast cancer is a tragic event for a woman. Caring
for breast cancer patients can increase the risk for
depression, anxiety, insomnia, and diminish
QOL.16 Health-related QOL (HRQOL), or QOL,
indicates a subjective and multidimensional
concept commonly composed of physical, social,
emotional, mental, and functional health
domains.17 In other words, QOL characterizes
the conditions of physical, psychological, and
social well-being.18 Due to the lack of studies on
this topic, this study aims to evaluate QOL in
Iranian breast cancer patients under  treatment with
the AC compared to the PG chemotherapy
regimens.
Materials and Methods
This was a cohort study conducted on 100
women diagnosed with breast cancer who attended
Nemazee Hospital, a referral center in Shiraz,
Southern Iran during March 2013 to March 2014.
We randomly assigned 100 patients with
pathological diagnoses of breast cancer to 2
categories. Group 1 received PG [paclitaxel (175
mg/m2) and gemcitabine (1000 mg/m2)] on days
1 and 8. Both regimens were repeated every 3
weeks for a total of 4 cycles of chemotherapy. All
patients had locally advanced breast cancer (stages
IIB or III). All women with pathologically proven
breast cancer; younger than 65 years of age;
advanced breast cancer diagnosis; and Karnofsky
performance status ≥70 were eligible to enter the
study. In addition, all patients had normal renal and
hepatic functions, Hb>9, platelets >100000, and
a neutrophil count >1500. The exclusion criteria
were: age more than 75 years; hypersensitivity to
the chemotherapeutic agents; distant metastasis;
history of chemotherapy; and abnormalities in
blood tests prior to onset of chemotherapy. The
present study was approved by the Ethics
Committee of Shiraz University of Medical
Sciences. The aim of the research and interview
method was explained to the participants. All
patients signed an informed consent. Patients who
refused to enter the study were also excluded.
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We used the European Organization for Research
and Treatment of Cancer QOL Questionnaire-
Core30 (QLQ-C30) to assessment QOL in these
patients.19 This questionnaire is a valid, reliable
questionnaire to evaluate QOL in Iran.20,21 The
EORTC QLQ-C30 is a 30-item questionnaire
composed of multi-item scales and single items
that reflect the multidimensionality of the QOL
construct. It incorporates five functional scales
(physical, role, cognitive, emotional, and social),
three symptom scales (fatigue, pain, nausea and
vomiting), and a global health and QOL scale.
Also six single items assess additional symptoms
commonly reported by cancer patients (dyspnea,
appetite loss, sleep disturbance, constipation,
diarrhea, and financial impact of the disease and
treatment). The scores are transformed into 0-
100 point scales. In the questionnaire, the highest
score in performance scale represents a better
level of functioning. The highest score in the
overall health-status scale represents a better level
of QOL. However, in the symptom scale, high
scores represent a worse level of symptoms.22
The data have been collected by patient interviews
during the first and last chemotherapy sessions. At
the beginning of each interview, we explained
the overall goal of the project and the interview
was explained to each patient separately.  In order
to compare the mean score of the two groups in
each interview, an independent t-test was used after
being assured of the normality of the data. P-
values less than 0.05 were considered statistically
significant.
Results
A total of 100 patients with locally advanced
breast cancer (stages IIB or III) participated in this
study. There were 50 women (50%) who received
the AC chemotherapy regimen and 50 women
(50%) who received the PG chemotherapy
regimen. Patients were between the ages of 28-70
years. In the AC regimen, the age range was 32-
70 years and for the PG regimen, patients were
28-68 years of age. The majority were married
(68%), 41-50 years of age (36%), not college
educated (76%), and had insurance (97%). Table
1 shows the patients’ demographic characteristics.
Table 2 shows a comparison of the mean QOL
scores at the first session of chemotherapy and
before revealing the therapeutic side effects. There
were no significant differences between the study
arms in different components of the questionnaire.
Analysis of the EORTC-QLQ-C30
questionnaire at the last session of chemotherapy
showed that the QOL in both groups deteriorated
as a result of side effects.
Table 3 compares the mean QOL scores at the
end of chemotherapy and after revealing the
therapy side effects. The function scales showed
that the AC arm had a significantly higher mean
score for the role, social, and cognitive functioning
compared to the PG arm.  The PG arm had a
higher mean score for emotional functioning
compared to the AC arm. There was no statistically
significant difference in physical performance
between both treatment arms.
The results of the symptoms scale of the
EORTC-QLQ-C30 questionnaire showed that
43Middle East J Cancer 2018; 9(1): 41-47
Quality of Life in Breast Cancer Patients Using Neoadjuvant Therapy
Table 1. Frequency according to the demographic characteristics of breast cancer patients.
Variable AC (n=50) PG (n=50) Patients N (%)
Age (years) ≤40 11 14 25 (25)
41-50 18 18 36 (36)
51-60 12 11 23 (23)
61-70 9 7 16 (16)
Marital Status Married 36 32 68 (68)
Single 14 18 32 (32)
Education College education 10 14 24 (24)
Non-college education 40 36 76 (76)
Insurance Yes 50 47 97 (97)
No 0 3 3 (3
AC: Doxorubicin and cyclophosphamide; PG: Paclitaxel and gemcitabine.
fatigue, pain, constipation, and economic status in
the AC arm were significantly better (lower mean
scores) compared to the PG arm. Nausea and
vomiting, dyspnea, insomnia, and diarrhea in the
PG arm were better (lower mean scores) compared
to PG arm.
A comparison of loss of appetite in both groups
showed no significant difference. Analysis of
global health status of the EORTC-QLQ-C30
questionnaire in the last session of chemotherapy
in both arms showed no significant difference.
Discussion
The QOL EORTC-QLQ-C30 is part of the
evaluation criteria for cancer therapy. Recently, it
has been recognized that a more comprehensive
assessment of the cancer patient is necessary and
the evaluation of outcomes must move beyond
traditional biomedical endpoints to include
assessments of the impact of disease and its
treatment on patient QOL.19 This study has
focused on women with stage IIB or III breast
cancer. Although not the most advanced stage of
disease, women with stage IIB or III breast cancer
experience tremendous distress due to their
diagnosis, treatment, and the fear of breast cancer
recurrence or metastases. In this follow-up study,
we have presented the results of a comprehensive
assessment of QOL in these patients treated with
the AC chemotherapy regimen compared to the
PG regimen. This study has shown that at the
end of chemotherapy, QOL in both groups
deteriorated as a result of the side effects and
reveals the difference from the initial results. The
toxicity of chemotherapy drugs causes side effects
that include bone marrow suppression, immune
system suppression, liver toxicity, skin disorders,
central nervous system disorders, and
genitourinary and gastrointestinal complications
such as inflammation of the lining of the mouth
and intestines.23 Hürny et al. have reported a
significant relationship between chemotherapy
and the QOL of women with breast cancer.24
Stein et al. showed that women with breast cancer
treated with radiotherapy and chemotherapy
suffered from poor sleep quality and had lower
QOL.25 Hatam et al. observed a vast increase in
side effects such as constipation, nausea,
stomatitis, fatigue, and alopecia during
chemotherapy.7 The results of the EORTC-QLQ-
C30 questionnaire at the last session of
chemotherapy in the current study showed that the
greatest problem in the functional scales for
patients who received the AC chemotherapy
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Table 2. Quality of life (QOL) in AC and PG groups at the first chemotherapy session.
AC PG P-value
Mean SD Mean SD
Functional status*
Physical 77.86 14.47 77.32 16.60 0.886
Role 67.99 18.69 67.32 15.77 0.758
Emotional 63.33 13.46 63.16 20.62 0.260
Cognitive 82.33 16.29 81.66 17.89 0.962
Social 82.66 15.41 82.33 18.26 0.820
Global health status/QOL 71.33 19.71 71.15 19.14 0.808
Symptoms**
Fatigue 24.44 15.55 24.88 16.73 0.891
Nausea and vomiting 4.99 9.66 4.33 11.06 0.315
Pain 25.33 21.62 25.66 21.08 0.751
Dyspnea 1.99 7.25 1.99 7.99 0.732
Insomnia 23.99 25.23 23.99 25.23 1.000
Appetite loss 31.99 25.15 31.99 26.04 0.994
Constipation 17.46 21.45 17.99 23.52 0.904
Diarrhea 0.66 4.71 0.66 4.71 1.000
Financial difficulties 35.99 26.79 35.99 19.57 0.965
*A high score represents a better level of functioning.; **A high score represents a worse level of symptoms.; AC:  Doxorubicin and cyclophosphamide;
PG: Paclitaxel and gemcitabine.
regimen was related to emotional function; patients
who received PG chemotherapy had a greater
problem with role function. Previous studies
indicated that breast cancer had the greatest effect
on role and emotional functions.26,27 This finding
was similar to the current study outcomes.
Analysis of the EORTC-QLQ-C30 questionnaire
in the symptom scales showed that financial
difficulties received the highest rating in both
arms; a higher score in this scale represented a
worse situation. Mohadesi et al., in a review on
QOL in patients with breast cancer, concluded that
the economic situation was the most important
concern that affected patients’ QOL.27 In this
study, the most common complication caused by
treatment in patients who received the AC
chemotherapy regimen was insomnia. Insomnia
is a sleep disorder characterized by trouble falling
sleep, staying asleep, or waking up too early.28 It
has been shown that insomnia is a common
problem in cancer patients which may occur with
greater frequency and/or severity in breast cancer
compared to other cancers.29-31 There is no
information on the impact of AC chemothera-
peutic agents on insomnia. A systematic review
has concluded that women with breast cancer
tended to report higher levels of sleep disturbances
upon receiving chemotherapy or radiotherapy.32
George et al. reported an association between
radiotherapy and chemotherapy with insomnia
in different types of cancers.33 Hatam et al.7
researched QOL and toxicity in breast cancer
patients who received adjuvant docetaxel,
doxorubicin, and cyclophosphamide (TAC)
compared doxorubicin, cyclophosphamide, and 5-
fluorouracil (FAC). They concluded that insomnia
was the most common complication in both
groups. We have observed that constipation was
the most common complication in the PG arm.
Although constipation is a significant side-effect
of cancer treatment,34-37 scant research has been
conducted into the underlying mechanisms.
Chemotherapy-induced constipation is recognized
as a mixture of reduced frequency of bowel action
and increased stool consistency.38 Increasing age
and female gender are thought to be associated
with an increased prevalence of constipation.39
Patients who received PG chemotherapy had a
significantly higher mean score for fatigue
compared to patients who received the AC
chemotherapy regimen. Higher average scores
in this scale have represented a worse situation.
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Table 3. Quality of life (QOL) in AC and PG groups at the last chemotherapy session.
AC PG P-value
Mean SD Mean SD
Functional status*
Physical 73.72 18.38 70.79 17.13 0.355
Role 68.32 17.25 58.66 12.25 0.000
Emotional 58.99 12.46 66.33 12.01 0.014
Cognitive 79.66 16.93 70.32 13.58 0.008
Social 79.32 16.68 68.99 15.43 0.016
Global health status/QOL 66.49 18.09 59.99 18.59 0.051
Symptoms**
Fatigue 31.10 8.39 44.88 19.04 0.000
Nausea and vomiting 38.66 16.64 25.99 19.38 0.003
Pain 28.99 19.86 39.32 15.34 0.006
Dyspnea 33.33 27.76 3.33 10.10 0.000
Insomnia 46.66 33.67 27.33 25.80 0.004
Appetite loss 35.99 29.22 41.32 27.40 0.246
Constipation 19.33 27.83 50.06 22.44 0.000
Diarrhea 7.33 13.94 1.99 7.99 0.022
Financial difficulties 54.66 27.56 66.86 26.46 0.031
*A high score represents a better level of functioning; **A high score represents a worse level of symptoms.; AC: Doxorubicin and cyclophosphamide;
PG: Paclitaxel and gemcitabine.
Fatigue has a profoundly negative impact on QOL
in patients with cancer by creating a tremendous
interaction with patient function. Fatigue is a
common symptom experienced by cancer
patients40,41 with a reported prevalence of 60%-
100%, considering the cancer type, stage, and
prescribed treatment.42 Mohadesi et al. have
concluded that fatigue was the most common
complication caused by treatment in patients with
breast cancer.27 The findings also showed that, in
addition to fatigue, patients in the AC arm had
significantly better scores (lower mean scores) for
pain, constipation, and economic status compared
to the PG arm. The symptoms of nausea and
vomiting, dyspnea, insomnia, and diarrhea in the
PG arm compared to the AC was better (lower
mean scores). A comparison of loss of appetite in
both groups showed no significant difference.
Analysis of the global health status in the last
session of chemotherapy showed no significant
difference between the AC and PG groups.
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